🇺🇸 UTHR — United Therapeutics Corporation
Salud CompraPrecio actual
601,32 USD
Máx. histórico
601,32
0 días
Split 2:1 del 23/09/2009
Caída desde máximo
En máximo
Rango 52 semanas
430,02 – 609,99
Variación hoy
+0,87%
Cierre anterior
596,13
Rango de hoy
596,14 – 606,16
Volumen hoy
595.233
Peor caída histórica
-93,18%
12/07/2000 → 10/12/2001
Recuperado en 3311 días
Volatilidad anualizada ⓘ
46,95%
- Nombre completo
- United Therapeutics Corporation
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Drug Manufacturers - Specialty & Generic
- Empleados
- 1.400
- PER ⓘ
- 21,54 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 670,93 USD (puede no estar actualizado)
- Primera cotización
- 17/06/1999
- Precio actualizado
- hace 18 horas
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Fecha | Ratio |
|---|---|
| 23/09/2009 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/12/2023 | 246,01 | 246,49 | 240,14 | 240,26 | -2,49% | 2,58% | 431.000 |
| 18/12/2023 | 247,86 | 248,22 | 243,63 | 246,40 | -0,02% | 1,85% | 380.900 |
| 15/12/2023 | 253,31 | 255,50 | 245,58 | 246,45 | -3,01% | 3,92% | 815.300 |
| 14/12/2023 | 257,10 | 258,31 | 252,61 | 254,09 | -1,11% | 2,22% | 387.500 |
| 13/12/2023 | 251,02 | 257,27 | 250,55 | 256,94 | +2,08% | 2,68% | 339.200 |
| 12/12/2023 | 246,17 | 252,08 | 244,75 | 251,70 | +2,79% | 2,98% | 303.800 |
| 11/12/2023 | 242,00 | 244,98 | 241,00 | 244,86 | +1,33% | 1,64% | 209.300 |
| 08/12/2023 | 243,17 | 244,41 | 240,09 | 241,65 | -0,17% | 1,78% | 210.200 |
| 07/12/2023 | 240,57 | 242,34 | 238,03 | 242,07 | +0,87% | 1,79% | 235.400 |
| 06/12/2023 | 240,31 | 242,45 | 239,00 | 239,98 | -0,14% | 1,44% | 193.200 |
| 05/12/2023 | 239,35 | 241,03 | 236,56 | 240,31 | +0,15% | 1,87% | 222.500 |
| 04/12/2023 | 240,04 | 243,75 | 237,25 | 239,94 | -0,33% | 2,71% | 258.300 |
| 01/12/2023 | 240,82 | 242,33 | 237,91 | 240,73 | +0,30% | 1,84% | 307.200 |
| 30/11/2023 | 234,48 | 241,32 | 234,00 | 240,00 | +3,42% | 3,12% | 482.600 |
| 29/11/2023 | 231,19 | 234,03 | 230,29 | 232,07 | +0,73% | 1,62% | 300.700 |
| 28/11/2023 | 230,34 | 231,66 | 228,76 | 230,39 | -0,31% | 1,26% | 293.700 |
| 27/11/2023 | 231,47 | 232,59 | 230,27 | 231,10 | -0,01% | 1,00% | 208.000 |
| 24/11/2023 | 232,00 | 232,77 | 230,03 | 231,13 | +0,28% | 1,18% | 103.800 |
| 22/11/2023 | 231,84 | 232,23 | 229,72 | 230,48 | +0,02% | 1,08% | 102.200 |
| 21/11/2023 | 228,58 | 233,15 | 228,58 | 230,43 | +0,63% | 2,00% | 176.400 |
| 20/11/2023 | 228,95 | 230,50 | 226,91 | 228,99 | +0,02% | 1,57% | 271.300 |
| 17/11/2023 | 228,21 | 229,01 | 226,14 | 228,94 | +1,02% | 1,26% | 180.000 |
| 16/11/2023 | 229,78 | 230,56 | 225,77 | 226,63 | -1,15% | 2,08% | 185.600 |
| 15/11/2023 | 227,50 | 231,82 | 227,50 | 229,26 | +0,39% | 1,90% | 235.400 |
| 14/11/2023 | 226,93 | 230,00 | 226,93 | 228,38 | +1,35% | 1,35% | 230.900 |
| 13/11/2023 | 222,14 | 225,57 | 221,61 | 225,34 | +1,12% | 1,78% | 158.600 |
| 10/11/2023 | 221,79 | 223,78 | 220,79 | 222,84 | +0,51% | 1,35% | 150.300 |
| 09/11/2023 | 226,42 | 226,74 | 219,12 | 221,72 | -1,78% | 3,37% | 235.500 |
| 08/11/2023 | 230,74 | 231,04 | 225,28 | 225,73 | -2,04% | 2,50% | 218.000 |
| 07/11/2023 | 228,66 | 231,98 | 227,15 | 230,44 | +0,99% | 2,11% | 318.200 |